Figure 7. B7 blockade dramatically inhibits primary xenospecific T-cell proliferation and alters phenotype of xenospecific proliferating T cells.

(a) VPD-450–based xenogeneic MLER was performed in the presence or absence of B7 inhibitor belatacept. Human T-cell proliferation in response to PECs was dramatically inhibited by belatacept. (b) Costimulation blockade with belatacept significantly reduced the MFI of CD2 expression on xenoreactive CD4⁺ proliferating cells when compared with resting and nonproliferating cells. (c) Belatacept significantly alters frequency of CD8⁺CD2^hiCD28⁻ and CD8⁺CD2^hiCD28⁺ subsets when compared with resting and nonproliferating cells (* p<0.05).